$RGBP Regen BioPharma, Inc. (OTCQB: RGBP) announced breaking news as it has, "commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Biotechnology and Oncology Markets Have Positive Projections http://prn.to/2ARQPN8
ALL comments are In My Own OPINION. Please Use Your Own DD for Stock Trading.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.